MPP Announces Licensing Plan For Global Generic PrEP Production

By Gabrielle Wanneh / June 1, 2022 at 12:20 PM
The United Nations-backed Medicines Patent Pool announced a potential licensing agreement Friday (May 27) that would allow low- and middle-income countries to manufacture generic versions of injectable pre-exposure prophylaxis (PrEP) for HIV. Cabotegravir is administered monthly or every two months, so wide-spread availability of the drug would go a long way toward reaching the goal of ending the HIV epidemic, MPP Executive Director Charles Gore said. “In particular, it could be a game-changer in prevention. It is critical that it...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.